I am a
Home I AM A Search Login

Papers of the Week

Papers: 19 Mar 2022 - 25 Mar 2022

Pharmacology/Drug Development

2022 Mar 22

Pain Manag

Erenumab for episodic migraine.


Datta A, Gupta S, Maryala S, Aggarwal V, Chopra P, Jain S
Pain Manag. 2022 Mar 22.
PMID: 35313740.


In this review, the authors provide an overview of erenumab, a monoclonal antibody used for the preventative treatment of episodic migraine by targeting the pathway. Randomized controlled trials have shown that erenumab is associated with a statistically significant decrease in monthly migraine days in patients with episodic migraine at monthly doses of 70 or 140 mg when given for a period of 9-12 weeks. analyses have also shown long-term maintenance of efficacy. Clinical trials have found erenumab at doses of both 70 and 140 mg to have a favorable safety profile. Erenumab faces significant limitations because of its high financial cost. Additional long-term real-world data are needed to understand the role of erenumab in the treatment of migraine.